Tirabrutinib
Tirabrutinib
Tirabrutinib (pronounced tee-rah-BROO-ti-nib) is a pharmaceutical drug used in the treatment of certain types of cancer, specifically B-cell malignancies.
Etymology
The name "Tirabrutinib" is derived from the drug's mechanism of action. "Tira" is short for "tyrosine kinase inhibitor," which refers to the drug's ability to inhibit the tyrosine kinase enzyme. "Brutinib" is a common suffix used in the names of drugs that inhibit Bruton's tyrosine kinase (BTK), a specific type of tyrosine kinase that is overactive in certain types of cancer.
Usage
Tirabrutinib is used in the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), two types of cancer that affect B cells. It works by inhibiting the activity of BTK, which is overactive in these types of cancer. By inhibiting BTK, tirabrutinib can slow the growth of cancer cells and induce apoptosis, or programmed cell death.
Related Terms
- Tyrosine kinase inhibitor: A type of drug that inhibits the activity of tyrosine kinases, enzymes that play a key role in cell growth and proliferation.
- Bruton's tyrosine kinase (BTK): A specific type of tyrosine kinase that is overactive in certain types of cancer.
- Chronic lymphocytic leukemia (CLL): A type of cancer that affects B cells, a type of white blood cell.
- Mantle cell lymphoma (MCL): A rare type of non-Hodgkin lymphoma that affects B cells.
External links
- Medical encyclopedia article on Tirabrutinib
- Wikipedia's article - Tirabrutinib
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski